OTCMKTS:ARPO - Aerpio Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.97 +0.07 (+3.68 %)
(As of 12/19/2018 05:21 AM ET)
Previous Close$1.90
Today's Range$1.90 - $2.06
52-Week Range$1.75 - $5.25
Volume178,400 shs
Average Volume50,918 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema. It also develops ARP-1536, a humanized monoclonal antibody that is in late stage preclinical development for the treatment of wet age-related macular degeneration; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a Phase 1a clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.

Receive ARPO News and Ratings via Email

Sign-up to receive the latest news and ratings for ARPO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Current SymbolOTCMKTS:ARPO
Previous Symbol


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares40,590,000
Market Cap$0.00
OptionableNot Optionable

Aerpio Pharmaceuticals (OTCMKTS:ARPO) Frequently Asked Questions

What is Aerpio Pharmaceuticals' stock symbol?

Aerpio Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ARPO."

How were Aerpio Pharmaceuticals' earnings last quarter?

Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) posted its quarterly earnings data on Wednesday, November, 7th. The company reported $0.28 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.34 by $0.06. The company earned $18.82 million during the quarter, compared to analysts' expectations of $18.67 million. View Aerpio Pharmaceuticals' Earnings History.

What price target have analysts set for ARPO?

3 analysts have issued 12 month target prices for Aerpio Pharmaceuticals' stock. Their forecasts range from $9.00 to $10.00. On average, they anticipate Aerpio Pharmaceuticals' share price to reach $9.6667 in the next twelve months. This suggests a possible upside of 390.7% from the stock's current price. View Analyst Price Targets for Aerpio Pharmaceuticals.

What is the consensus analysts' recommendation for Aerpio Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerpio Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerpio Pharmaceuticals.

What are Wall Street analysts saying about Aerpio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerpio Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Aerpio Pharmaceuticals Inc. is a biopharmaceutical company. It focuses on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The Company' product candidates include AKB?9778, ARP1536 and AKB-4924 which are in clinical stage. Aerpio Pharmaceuticals Inc. is based in Cincinnati, United States. " (10/16/2018)
  • 2. HC Wainwright analysts commented, "Our 12-month price target is derived from a market value of the firm at $350M, which includes a discounted cash flow-based asset value for AKB-9778 and AKB-4924, using a 15% discount rate and 2% terminal growth rate, and probabilities of success at 30% and 10%, respectively. Risks include, but are not limited to: (1) failure of AKB-9778 or AKB-4924 in clinical trials; (2) failure of AKB-9778 or AKB-4924 to secure regulatory approval; (3) failure of AKB-9778 or AKB-4924 to achieve commercial success due to market size, penetration rate, or competition; and (4) dilution risk." (8/15/2018)

Has Aerpio Pharmaceuticals been receiving favorable news coverage?

Media headlines about ARPO stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aerpio Pharmaceuticals earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days.

Who are some of Aerpio Pharmaceuticals' key competitors?

Who are Aerpio Pharmaceuticals' key executives?

Aerpio Pharmaceuticals' management team includes the folowing people:
  • Dr. Joseph H. Gardner, Founder, Pres & Director (Age 62)
  • Mr. Kevin G. Peters M.D., Ph.D., Chief Scientific Officer & Sr. VP (Age 61)
  • Dr. Stephen Pakola M.D., Chief Medical Officer (Age 49)
  • Dr. Stephen J. Hoffman, CEO & Director (Age 64)
  • Mr. Michael W. Rogers, Chief Financial Officer (Age 58)

Who are Aerpio Pharmaceuticals' major shareholders?

Aerpio Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Sphera Funds Management LTD. (2.79%), Vanguard Group Inc (2.66%), Vanguard Group Inc. (2.66%), FMR LLC (1.39%) and Granite Point Capital Management L.P. (0.99%). Company insiders that own Aerpio Pharmaceuticals stock include Bioventures Ltd Novartis, Muneer A Satter and Stephen J Hoffman. View Institutional Ownership Trends for Aerpio Pharmaceuticals.

Which major investors are selling Aerpio Pharmaceuticals stock?

ARPO stock was sold by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P. and FMR LLC. View Insider Buying and Selling for Aerpio Pharmaceuticals.

Which major investors are buying Aerpio Pharmaceuticals stock?

ARPO stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc, Vanguard Group Inc. and Sphera Funds Management LTD.. Company insiders that have bought Aerpio Pharmaceuticals stock in the last two years include Muneer A Satter and Stephen J Hoffman. View Insider Buying and Selling for Aerpio Pharmaceuticals.

How do I buy shares of Aerpio Pharmaceuticals?

Shares of ARPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aerpio Pharmaceuticals' stock price today?

One share of ARPO stock can currently be purchased for approximately $1.97.

What is Aerpio Pharmaceuticals' official website?

The official website for Aerpio Pharmaceuticals is http://www.aerpio.com.

How can I contact Aerpio Pharmaceuticals?

Aerpio Pharmaceuticals' mailing address is 9987 CARVER ROAD, CINCINNATI OH, 45242. The company can be reached via phone at 513-985-1920 or via email at [email protected]

MarketBeat Community Rating for Aerpio Pharmaceuticals (OTCMKTS ARPO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  36 (Vote Outperform)
Underperform Votes:  32 (Vote Underperform)
Total Votes:  68
MarketBeat's community ratings are surveys of what our community members think about Aerpio Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel